Schwab Charles Investment Management Inc. raised its stake in Cambrex Co. (NYSE:CBM) by 11.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 167,884 shares of the biotechnology company’s stock after buying an additional 17,775 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.51% of Cambrex worth $9,234,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the business. BlackRock Inc. lifted its stake in Cambrex by 0.5% in the second quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock valued at $240,409,000 after buying an additional 20,652 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Cambrex by 0.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,330,254 shares of the biotechnology company’s stock valued at $79,483,000 after purchasing an additional 11,762 shares in the last quarter. FMR LLC raised its stake in shares of Cambrex by 19.1% during the second quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock valued at $63,971,000 after purchasing an additional 171,559 shares in the last quarter. State Street Corp raised its stake in shares of Cambrex by 5.1% during the second quarter. State Street Corp now owns 779,820 shares of the biotechnology company’s stock valued at $46,600,000 after purchasing an additional 37,669 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Cambrex by 3.7% during the second quarter. Northern Trust Corp now owns 566,302 shares of the biotechnology company’s stock valued at $33,837,000 after purchasing an additional 19,955 shares in the last quarter.
CBM has been the topic of a number of recent analyst reports. Craig Hallum restated a “buy” rating and set a $60.00 price objective (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. Zacks Investment Research upgraded shares of Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $62.33.
Shares of Cambrex Co. (CBM) opened at $51.65 on Tuesday. Cambrex Co. has a one year low of $42.55 and a one year high of $62.95. The firm has a market cap of $1,692.96, a PE ratio of 17.22, a P/E/G ratio of 1.25 and a beta of 2.27.
Cambrex (NYSE:CBM) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.08. The business had revenue of $112.60 million for the quarter, compared to analysts’ expectations of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The company’s revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.47 earnings per share. sell-side analysts forecast that Cambrex Co. will post 2.97 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2018/01/16/schwab-charles-investment-management-inc-boosts-stake-in-cambrex-co-cbm.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.